Schering Aktiengesellschaft

Bayer Schering Pharma Ag

Bayer Intellectual Property Gmbh

Hermann Kuenzer

Rolf Bohlmann

Christa Hegele-Hartung

Monika Lessl

Karl-Heinrich Fritzemeier

Yukishige Nishino

Rosemarie Lichtner

Jorg Kroll

Wolfgang Schwede

Ludwig Zorn

Hans-Peter Muhn

Antonius Ter Laak

Dieter Zopf

Reinhard Nubbemeyer

Hans Briem

Dirk Kosemund

Dieter Bittler

Rolf Jautelat

Benjamin Bader

Karl-Heinz Thierauch

Georg Kettschau

Stuart Ince

Ulrike Fuhrmann

Peter Esperling

Ursula Moenning

Steffen Borden

Katja Prelle

Ulf Boemer

Roman Hillig

Gerd Mueller

Uwe Kollenkirchen

Manfred Husemann

Rudolf Knauthe

Martina Schaefer

Arndt Schmitz

Norbert Gallus

A 18-Methyl-19-nor-17-pregn-4-ene-21,17-carbolactone of general formula I 

18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter

This invention relates to compounds of general formula I in which Rand Rare described in this application, the use of the compounds of general formula I as inhibitors of protein tyrosine kinases for treatment of various diseases as well as the compounds of general formulas II and III as intermediate compounds for the production of compounds of general formula I, wherein X, Rand Rhave the meaning that is described in general formulas II and III.

3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents

The invention relates to pyrazolopyridines according to the general formula (I): and salts thereof, to pharmaceutical compositions comprising said pyrazolopyridines and to a method of preparing said pyrazolopyridines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with angiopoietin and therefore influence Tie2 signalling.

Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same

The invention relates to 11&#x3b2;-halogen steroids with general formula (I), whereby Ris halogen, X&#x2014;Y-Z represents a group with one of the two structures CH&#x2550;C&#x2014;C or CH&#x2014;C&#x2550;C and the other radicals have the meaning that is indicated in the claims, also the production and use of these compounds for the production of pharmaceutical agents as well as pharmaceutical preparations that contain 11&#x3b2;-halogen steroids.

Androgenic 7-substituted 11-halogen steroids

A novel method of synthesis for the manufacture of upstream products for the production of compounds with general formulas 8, 10, and 12 is described. In this synthesis, compounds with general formula 4,B are produced in a microbiological reaction. The meanings of R, R, R, R, Rand Ras well as of the grouping U&#x2014;V&#x2014;W&#x2014;X&#x2014;Y&#x2014;Z are indicated in the claims 

Microbiological process for the production of 7-substituted 11-hydroxy steroids, 7,17-substituted 11-Halogen steroids and uses thereof

Benzocycloheptenes of formula (I), in which R, Rand Y have the meanings that indicated herein, exhibit selective estrogenic activity on bones and are suitable for the production of pharmaceutical agents, especially for prophylaxis and therapy of osteoporosis: 

Benzocycloheptenes, process for their production, pharmaceutical preparations that contain that latter as well as their use for the production of pharmaceutical agents

The invention describes new compounds as pharmaceutical active ingredients, which have in vitro a higher affinity to estrogen receptor preparations from rat prostates than to estrogen receptor preparations from rat uteri and in vivo a preferential action on bone rather than the uterus, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds. The new compounds are 16&#x3b1;- and 16&#x3b2;-hydroxy-estra-1,3,5(10)-estratrienes, which carry additional substituents on the steroid skeleton and can have one or more additional double bonds in the B-, C- and/or D-rings.

16-hydroxyestratrienes as selectively active estrogens

This invention describes the new benzocycloheptenes of general formula Iin which

Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents

This invention describes the new 4-fluoroalkyl-2H-benzopyrans of general formula I,in which The new compounds have at their disposal strong antiestrogenic action. In addition, they can have at their disposal estrogenic action that occurs in a tissue-selective manner. They can be used for the production of pharmaceutical agents, especially for the treatment of estrogen-dependent diseases and tumors and pharmaceutical agents for hormone replacement therapy (HRT) as well as for the prevention and treatment of osteoporosis.

4-fluoroalkyl-2h-benzopyrans with anti-estogenic activity

Growing community of inventors

Berlin, Germany

Hermann Kuenzer